Healthcare & Pharmaceutical Market Research in Italy

BioNixus is a leading healthcare market research company in Italy, delivering AIFA-aligned HCP surveys, KOL mapping, and payer landscape research aligned with AIFA, SSN, and regional SSR requirements. BioNixus combines primary research depth with physician access across Italian IRCCS institutions and major academic medical centres, with all fieldwork conducted in Italian.

A healthcare market research company in Italy designs and executes studies covering physician prescribing behaviour, AIFA CTS/CPR payer and formulary access dynamics, patient journeys, KOL influence mapping at IRCCS institutions, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the Italian market.

Italy operates a universal SSN (Servizio Sanitario Nazionale) with 20 regional SSR systems that can impose additional formulary restrictions on top of national AIFA PFN listing. AIFA's dual CTS/CPR process — where CTS classifies innovation level and CPR negotiates price — is distinct from Germany's G-BA AMNOG or France's HAS/CEPS combined process. Italy's 49 IRCCS institutions concentrate clinical research and KOL influence in ways unique among EU5 markets. Regional SSR variation in Lombardia, Lazio, Veneto, and Emilia-Romagna creates a second access layer requiring dedicated regional payer research.

BioNixus covers oncology (AIOM guidelines, IRCCS oncology centres, AIFA Law 648/96 compassionate use), immunology and biologics (biosimilar policies, AIFA biosimilar switching), cardiovascular, diabetes and metabolic (including GLP-1), rare disease (AIFA 648/96 and registro AIFA), respiratory, infectious disease (HIV, HCV), neurology, medical devices (CEQ/MDR), and consumer health across the Italian market.

Yes. BioNixus maintains physician and specialist networks across Italian IRCCS (INT Milan, IEO, ISS Rome, CEINGE Naples), Policlinico Gemelli Rome, Humanitas Milan, Sant'Orsola Bologna, and Policlinico di Torino. For scarce specialties such as oncology or rare disease, we recruit through IRCCS cancer centre networks, rare disease specialist directories, AIOM (oncology), SIR (rheumatology), and SIMG (general medicine) specialist society contacts.

Focused Italian HCP surveys complete in 3–4 weeks. Full mixed-method programmes including AIFA payer depth interviews and SSR regional formulary modules typically run 6–10 weeks depending on therapy area, CE IRCCS ethics review requirements, and respondent scarcity. Oncology and rare disease KOL programmes with multi-IRCCS recruitment across Northern, Central, and Southern Italy may require extended planning timelines.

Yes. BioNixus designs and executes Italian patient research in compliance with GDPR and the Italian Privacy Code (D.Lgs. 196/2003 as amended by D.Lgs. 101/2018). All patient and caregiver research involves documented informed consent, de-identified reporting, Garante Privacy-compliant data handling, and where required, Italian CE (Comitato Etico) ethics review coordination.

Yes. Italian modules can run with comparable cells in Germany, France, Spain, and the UK — and beyond to the USA, Canada, Japan, and other markets — using consistent instruments for global portfolio committees managing EU5 and multi-market access strategy from one research partner.